Publish date:

Novan Only Piercing the Skin of Its Potential Says CEO

With a pair of Phase III trials coming up for its dermatological drug, Novan CEO Nate Stasko says the company is merely piercing the skin of its long-term potential.

Novan's (NOVN) - Get Report stock is trading at nearly double last month's $11 IPO price and with a pair of Phase III trials coming up for its dermatological drug, CEO Nate Stasko says the company is merely piercing the skin of its long-term potential. Stasko estimated between 40 and 50 million Americans suffer from acne vulgaris and can be helped by his nitric oxide-based treatment. Nitric oxide is made in the skin by almost every cell type. It has a natural role in barrier repair, wound healing, host defense against invading microbes, and as a modulator of inflammatory processes. But in many chronic inflammatory skin diseases and in skin infections, the body's systems fail and require a boost of nitric oxide to 'reprogram' the system or kill bacteria, viruses, or fungi. Novan's two, identically designed Phase 3 pivotal clinical trials will evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 Gel in the treatment of acne vulgaris. These two trials aim to demonstrate the safety and efficacy of SB204 in over 2600 patients with acne vulgaris.

TST Recommends